About
Marc Bjurlin, DO received his medical degree from Midwestern University and completed his residency at the Cook County Hospital in Chicago. After residency, Dr Bjurlin completed a fellowship in urologic oncology at New York University along with a master of science degree in clinical investigation through the New York University School of Medicine. Prior to joining UNC, Dr. Bjurlin was Assistant Professor of Urology and Director of Urologic Oncology at NYU Langone Hospital in Brooklyn and was recently selected by Super Doctors for a “Rising Star” distinction in the New York Metro area.
Dr. Bjurlin’s clinical practice is focused on urologic oncology—in particular, the treatment of bladder, prostate, testis, and kidney cancer. He is a member of the integrated Multidisciplinary Genitourinary Oncology Group at the Lineberger Comprehensive Cancer Center. His team takes a collaborative approach to create a personalized treatment. Dr. Bjurlin’s expertise has allowed him to serve on national committees that establish care guidelines for the management of cancers of the urinary tract including the American Urological Association’s committee on the Standard Operating Procedure for Prostate Magnetic Resonance Imaging.
In addition to patient care, Dr. Bjurlin participates in research focused on employing advanced surgical procedures including the use of robotic surgery to maximize the quality of life for people with urologic malignancies. He is also a member of the American Urological Association New Technology and Imaging Committee
Specialties
Publications
Education
Fellowship: NYU School of Medicine, New York, NY
Residency: Cook County Health and Hospitals, Chicago, IL
DO: American College of Osteopathic Medicine & Surgery, Chicago, IL
Schedule an Appointment with Dr. Bjurlin
UNC Urology Medical Center Office
UNC Urology NC Cancer Hospital Office
Refer a Patient to Dr. Bjurlin
Medical professionals interested in referring a patient please visit our Refer a Patient page for more information.
News
1 month ago
UNC Urology Participates in Cutting Edge Clinical Trial of Potential New “Combination Therapy” for Bladder Cancer
A multi-center Phase 3 clinical trial named “QUILT” is exploring a potential new treatment that involves administering BCG (Bacillus Calmette-Guerin) combined with an experimental drug known as N-803 (Nogapendekin alfa inbakicept), with the goal of providing a synergistic therapeutic effect to some Bladder Cancer patients.
2 months ago
UNC Urology’s Dr. Marc Bjurlin Spotlights Prostate Cancer on ABC11 Eyewitness News
UNC Urology Associate Professor and Director of Clinical Trials, Dr. Marc Bjurlin, spoke on a recent ABC11 Eyewitness News segment addressing Prostate Cancer Awareness. The segment, led by Bianca Holman, sheds light on the heightened risk for prostate cancer faced by black men.